Inventiva's Stock Rises 8.97% at Opening, Driven by a Strong Upward Trend
The share of the French biotech company shows a sharp increase this Tuesday morning, crossing the €4.80 mark after closing at €4.41 the previous day. This acceleration of movement is part of a longer-term dynamic that is particularly strong, with an increase of 21.83% over the past week and 124.3% over the past twelve months, far exceeding the CAC 40's performance, which is up 12.23% over the same period. However, volumes remain moderate, with only 0.17% of the capital in circulation.
Technically, the stock is breaking through several key levels above its short-term moving averages. The price is now €1.31 above the 50-day moving average of €3.69, confirming a short-term bullish dynamic that extends well beyond the 200-day moving average of €3.46, highlighting the strength of the overall trend. Monthly volatility stands at 14.44%, a level that the ATR of €0.10 translates into an average amplitude of daily movements. Today's progress easily absorbs this usual volatility, indicating a significant acceleration compared to recent fluctuations.
Market Indicators
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The Relative Strength Index reaches 75, a threshold generally associated with overbought conditions where a correction could occur. The stochastic shows a buy signal, creating a signal divergence with the high RSI. Meanwhile, the MACD remains moderately positive with a line at 0.14 and a signal at 0.10, indicating rising momentum but without excessive overflow. The positive Chaikin Money Flow at 0.17 indicates the presence of buying flows, contradicting the negative signal from the OBV which suggests limited volume accumulation. The stock is currently in the upper part of the Bollinger Bands, between €3.52 and €4.28, without exceeding the upper limit, reflecting contained volatility despite today's progress.
Technical Support and Resistance
Immediate resistance remains at €4.41, yesterday's level, while technical support is established at €3.45, offering a gap of €1.35 between these two zones. The beta of -0.64 indicates that this stock generally moves in the opposite direction of the broader market, a characteristic that may explain its progress while the CAC 40 slightly declines by 0.23% during the session. This decorrelation underscores the inherent strength of the ongoing bullish movement in the stock.
Position de trésorerie au 30/09/2025 de 97,6 millions d’euros (plus 24,7 millions d’euros en dépôts à court terme) ; revenus de 4,5 millions d'euros sur les neuf premiers mois de 2025 principalement liés à CTTQ ; flux opérationnels consommés de - 76,3 millions d’euros et flux d'investissement de - 25 millions d’euros ; flux de financement positifs de 103,4 millions d’euros incluant le produit net de la deuxième tranche du financement structuré. Offre publique en novembre 2025 d’ADS apportant un produit net d’environ 139,3 millions d’euros et estimation d’un horizon de trésorerie jusqu’à fin T1 2027 (pouvant aller jusqu’à mi-T3 2027 si exercice intégral de la Tranche 3 pouvant apporter 116,0 millions d'euros).
Risks mentioned
Besoin de capitaux supplémentaires pour financer les opérations
Risque que la Société utilise ses ressources plus rapidement que prévu
Incertitudes et risques liés aux essais cliniques et aux autorisations réglementaires
Dépendance au succès du lanifibranor et des résultats de l'essai NATiV3
Opportunities identified
Produit net de l’offre publique en novembre 2025 d’environ 139,3 millions d’euros renforçant la trésorerie
Exercice potentiel de la Tranche 3 pouvant apporter jusqu’à 116,0 millions d'euros supplémentaires
Paiement d'étape et avoirs liés à l’accord avec CTTQ (10 M$ et 5 M$)
Résultats principaux de l’essai NATiV3 attendus au second semestre 2026
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
